JSR Life Sciences Launches 'Similis Bio' to Help Partners Accelerate Biosimilar Development
10.5.2022 15:00:00 EEST | Business Wire | Press release
JSR Life Sciences, LLC (JSR) today announced the launch of a new business division, Similis Bio (Similis), which will operate a partnering program designed to help biopharmaceutical companies improve the efficiency and cost of biosimilar development. Similis will rely on core expertise in developing and manufacturing biologics to mitigate the challenges inherent in biosimilar drug development.
Similis provides biosimilar drug developers with solutions designed to accelerate development timelines and lower costs. By offering complete analytical and process development packages, Similis supplies companies with data to determine an appropriate biosimilar target, accelerate early program development, and reduce analytical costs. Data packages include reference product data, analytical procedures, process expertise, and CMC templates from a centralized model designed to give partners access to higher quality biosimilar packages at a lower cost than other development models.
Additionally, Similis will establish co-development agreements with partner companies to start the development of multiple biosimilar programs in parallel, giving partners an exclusive right, but not an obligation, to purchase multiple programs. JSR designed this collaboration model to reduce the risk from program cancellations and extend market analysis timelines.
“This model will enable changes in strategy far beyond traditional drug development approaches by centralizing reference product data and expertise under one roof,” said JSR Life Sciences’ Chief Technology Officer Jean-Pierre Wery. “Similis brings the broad expertise of JSR Life Sciences companies together to jump-start the development of promising biosimilars. By improving timelines and development costs for drug makers, more biosimilars can be brought to market faster. Ultimately, that means more choice and lower costs for patients.”
Biosimilars—the generic form of FDA-approved biologics—are derived from living organisms, making them inherently complex. Unlike small-molecule generic drugs, biosimilars cannot fully replicate their brand-name counterparts, so an array of analytical data must be collected to ensure they sufficiently reflect biosimilarity to the FDA-approved reference products to which they are being compared. This process requires costly and significant investment in expertise, state-of-the-art technology, and extensive data gathering, including rigorous clinical trials to ensure a biosimilar's safety and efficacy. JSR launched Similis Bio to mitigate these barriers to market entry and promote more productive development programs.
For more information about Similis Bio visit: JSRLifeSciences.com/similis.
About JSR Life Sciences, LLC
A business unit of JSR Corporation, JSR Life Sciences, LLC is changing human health as a strategic partner and pathfinder for the life sciences industry. Rooted in a history of materials innovation, JSR Life Sciences provides specialized products, materials, and services to biopharmaceutical companies and academic researchers. Together with its world-class affiliates, JSR Life Sciences offers best-in-class integrated services that de-risk molecule selection, accelerate biologic development timelines, increase clinical success rates, and develop novel in vitro diagnostics. JSR Life Sciences’ global network of affiliates includes Crown Bioscience, KBI Biopharma, Inc., Selexis SA, and MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. The company operates R&D and applications labs, manufacturing facilities, and sales offices worldwide. For more information, visit JSRLifeSciences.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220510005401/en/
Contact information
Missy Bindseil
JSR Life Sciences Company Inquiries
Director, Marketing & Communications
mbindseil@jsr-nahq.com
Mike Beyer
JSR Life Sciences Media Inquiries
Sam Brown Inc.
mikebeyer@sambrown.com
+1 312-961-2502
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AB InBev Turns Bars into Stadiums During Biggest-Ever FIFA World Cup™8.6.2026 15:00:00 EEST | Press release
Today, AB InBev, the world’s leading brewer, launched its global “Cheers to Bars” platform – a celebration of local bars and their impact on communities all over the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608956519/en/ Bars have always been more than places to grab a beer. They are where people come together to connect, celebrate milestones, build friendships, and create lasting memories. As hubs of social connection, bars play an important role in strengthening communities and bringing people closer together. “During the FIFA World Cup 2026™, bars will become the beating heart of every neighborhood – places where strangers become friends, every goal is celebrated as one, and collective memories are created with every raised glass,” said Michel Doukeris, CEO, AB InBev. “Beer and football have long been catalysts for bringing people together to create moments of joy and belonging. Nowhere is this spirit of b
Seequent and Cascade Institute Partner to Map Canada’s Deep Geothermal Resources8.6.2026 15:00:00 EEST | Press release
Seequent, The Bentley Subsurface Company, and the Cascade Institute today announced a collaboration to develop a Canadian Thermal Model. This landmark national initiative will reveal Canada’s deep geothermal resources and accelerate the development of renewable energy. The announcement comes on the opening day of the world’s biggest geothermal event, the World Geothermal Congress, being held in Calgary from 8 to 11 June. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608741816/en/ The Canadian Thermal Model will integrate over 20 input layers of geoscientific data related to geothermal energy to evaluate Canada’s nationwide deep heat resources. As investment in geothermal energy surges globally as a reliable, always-on clean power source, the Canadian Thermal Model will create a comprehensive national view of deep heat resources using novel machine learning methods to address a long-standing challenge for the sector: limi
NTT DATA Expands Collaboration with Google Cloud to Accelerate Enterprise AI from Pilots to Production8.6.2026 15:00:00 EEST | Press release
NTT DATA, a global leader in AI, digital business and technology services today announced an expanded collaboration with Google Cloud to help enterprises move from AI experimentation to scaled deployment of agentic AI solutions built with Gemini Enterprise. The collaboration is focused on enabling AI-powered reinvention, helping enterprises redesign processes, operating models and customer experiences using agentic AI. The collaboration combines Google Cloud’s AI, data and cloud platform capabilities with NTT DATA’s global delivery scale and deep industry expertise across strategy, implementation, adoption, managed services and value realization. Together, the companies will help clients embed AI into core workflows, improve productivity, accelerate time-to-value and support governance, security, compliance and responsible use of AI. NTT DATA is establishing a dedicated global Gemini Enterprise practice, backed by joint business planning, technical enablement, training, certifications,
Aptiv Introduces Advanced Occupancy Classification, The Industry’s First Camera-Only Occupant Detection System8.6.2026 15:00:00 EEST | Press release
Aptiv PLC (NYSE: APTV), a global industrial technology company, today announced the launch of its Advanced Occupancy Classification (AOC) system, the industry’s first occupant detection solution powered entirely by an in-cabin camera. The system simplifies vehicle architecture by eliminating traditional in-seat hardware while enabling next-generation cabin intelligence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608385007/en/ Aptiv’s Advanced Occupancy Classification (AOC) replaces traditional in-seat hardware with a vision-based software solution—reducing both system complexity and cost. Built on more than two decades of Aptiv leadership in occupant detection, AOC is an advanced software solution that leverages artificial intelligence (AI) and computer vision to accurately classify occupants based on parameters such as height, weight, and body position. This enables optimized airbag deployment decisions while signifi
Xylem Expands Long-Term Water Partnership with Dow8.6.2026 15:00:00 EEST | Press release
Xylem (NYSE: XYL), a leading global water technology company, today announced a landmark agreement with Dow (NYSE: DOW) to design, build and operate advanced water systems at its large-scale industrial complex in Fort Saskatchewan, Alberta, Canada. The agreement expands Xylem’s long-standing collaboration with Dow, supporting the increased operations tied to Dow’s Path2Zero project. Under the agreement, Xylem will deliver a full end-to-end solution that includes engineering, system design, and long-term operation. The project is designed to support reliable, high-quality water supply, treatment, and reuse across the site. The system is expected to be operational by August 2028. “This agreement represents a major milestone for Xylem,” said Rodney Aulick, EVP and President, Water Solutions and Services at Xylem. “It reflects the strength of our long-standing relationship with Dow and the deep trust we’ve built with a key customer over time. Strong customer relationships are central to ho
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom